Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Man triggers smoke bomb during failed crypto robbery - 2The most effective method to Refresh the Infotainment Framework in the Volvo XC40
- 3Artemis II astronauts will see parts of the moon no human has before. Here’s how
- 4Surveys of Music Collections by Film Stars
- 5Very good quality Greens All over The Planet
- CDC's upcoming vote on hepatitis B vaccine could impact childhood immunization
- IDF strikes terror infrastructure across Iran, attack reported on Kashan airport
- Understanding climate change in America: Skepticism, dogmatism and personal experience
- Struggling to keep your New Year's resolutions? Here's how to keep yourself on track
- Heat Wave Fuels Massive Wildfire In Australia
- Is Trump going to war with Venezuela?
- SpaceX's 1st 'Version 3' Super Heavy Starship booster buckles under pressure during initial tests
- Shah Capital pushes for Novavax sale, warns of proxy fight
- Figure out How to Assess the Unwavering quality of SUVs for Seniors
